IL1B and atherosclerosis: Anti-inflammatory therapies, such as IL1B antagonism and colchicine, reduce the incidence of clinical events in patients with advanced atherosclerosis (52, 53), but whether this is achieved partly by increasing cap thickness is also unknown.